Evaluating the Feasibility of Point of Care Birth Testing in Eswatini

NCT ID: NCT04206878

Last Updated: 2021-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3316 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess the feasibility and utility of birth testing using point-of-care (POC) testing in maternity settings in Eswatini.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This UNITAID-funded study aims to assess feasibility and utility of birth testing, \[early infant diagnosis for HIV, (EID)\], using point-of-care (POC) HIV nucleic acid testing (NAT) at high volume maternity settings. Birth testing is defined as tests within 3 days of life. Outcome measures will include age at testing, turnaround time from testing to caregiver result receipt, HIV positivity rate, and timing of anti-retroviral therapy (ART) initiation for HIV-positive infants. The study will document retention in care for those who tested positive at birth, and the percent of those who tested negative at birth who returned for six week testing. The study will also assess the feasibility and acceptability of POC birth testing using interviews with policymakers, health care workers and caregivers of HIV-exposed infants (HEI).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections HIV/AIDS Pediatric HIV Infection Transmission, Perinatal Infection Infant Morbidity Neonatal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-exposed infants (HEI) eligible for birth testing

All HEI live births born at, or presenting to, one of the 3 study sites, within 3 days of birth.

Point-of-care birth test

Intervention Type DIAGNOSTIC_TEST

Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Point-of-care birth test

Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV Exposed Infants

* Must have been newly born at the study sites or presenting in study sites within 3 days after birth
* Tested for HIV using POC EID platform (mother or caregiver agreed to have infant tested)
* Health Care Workers (HCWs)

* HCWs who have used POC EID for at least three months, at project sites
* HCWs that work directly with POC EID services at maternity providing clinical services or operating the platform
* HCWs who consent to be interviewed
* HCWs able to speak one of the study languages
* Laboratory Managers and program leads/focal persons:

* National or regional level manager or head of department whose responsibilities include EID
* Member of a national technical working group or advisory board member working on EID
* National level representative from the MOH
* Laboratory managers in the 3 study sites
* Participants 18 years and above who consent to be interviewed
* Mothers/caregivers:

* Mother/caregiver of an HEI who was offered POC EID at birth
* Provides consent to participate in the study
* Is 18 years or older, or is less than 18 years old but is legally married (and thus legally emancipated)
* Speaks one of the study languages

Exclusion Criteria

* HEIs:

* HEI tested for HIV using conventional EID at projects sites
* HEI whose caregivers refuse birth testing
* HEI where the clinician deems there is a contra-indication for sample collection for birth testing (e.g. severe hemophilia)
* HCWs:

* HCWs who work within project sites that do not make use of EID (i.e. HCWs who are not involved directly with EID)
* HCWs working in non-project sites
* HCWs who are unable to consent or do not speak a study language
* Laboratory Managers and program leads/focal persons:

* Inability to give consent
* Inability to speak study language
* Mothers/Caregivers:

* Not eligible for POC birth testing services
* Not able to consent
* Does not speak English or SiSwati
Maximum Eligible Age

4 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UNITAID

OTHER

Sponsor Role collaborator

Elizabeth Glaser Pediatric AIDS Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jennifer Cohn

Role: STUDY_DIRECTOR

Elizabeth Glaser Pediatric AIDS Foundation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mbabane Government Hospital, Hlathikhulu Hospital, and Good Shepherd Hospital

Mbabane, , Eswatini

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Eswatini

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EG0206

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.